Page 927 - Hematology_ Basic Principles and Practice ( PDFDrive )

810 Part VII Hematologic Malignancies

TABLE Mixed Lineage Leukemia Translocations and Rearrangements 2015—cont’d
56.9
# Cytogenetic Abnormality Breakpoint Hugo Name Leukemia Type
17 t(10;11)(q25;q23)
18 t(11;11)(q11;q23)
19 t(11;11)(q13;q23)
20 t(11;11)(q21;q23)
21 t(11;12)(q23;p13)
22 t(11;12)(q23;q13)
23 t(11;12)(q23;q24)
24 t(4;13;11)(q21;q34;q23)
25 t(11;14)(q23;q11)
26 t(11;14)(q23;q32)
27 t(11;15)q23;q15)
28 t(11;17)(q23;q11)
29 t(11;17)(q23;q23)
30 t(11;18)(q23;q12)
31 t(11;18)(q23;q23)
32 t(11;20)(q23;q13)
33 t(11;21)(q23;q11)
34 t(Y;11)(p11;q23)
35 t(X;11)(q22;q23)
AL, Acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BAL, biphenotypic acute leukemia; CML, chronic myelogenous leukemia; JMML,
juvenile myomonocytic leukemia; MDS, myelodysplastic syndrome; t-AL, therapy-related AL; t-ALL, therapy-related ALL; T-ALL, T-cell ALL; t-AML, therapy-related AML;
t-CML, therapy-related CML; t-MDS, therapy-related MDS; t-T-ALL, therapy-related T-cell ALL.
Courtesy C. Meyer and Rolf Marschalek, Diagnostic Center of Acute Leukemia (DCAL), Institute for Pharmaceutical Biology, Goethe University, Frankfurt, Germany,
February 14, 2015.

t(9;11)(p22;q23)
9
11
1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 X Y
A 46,XY,t(9;11)(p22;q23) B
Fig. 56.34 THE MOST FREQUENT MLL TRANSLOCATION IS t(9;11)(p22;q23). (A) The G-banded
karyotype and (B) a partial karyotype, from another metaphase, after hybridization with dual color “break-
apart” MLL probe showing the 5′ MLL (green) being retained on 11q23 and the 3′ MLL (red) moved as a
result of the translocation to 9p22. This translocation results in a fusion of MLLT3-AF9.